Does psilocybin work for treatment-resistant depression?

Yes. A 2022 Nature Medicine RCT found that two doses of psilocybin produced antidepressant effects equivalent to six weeks of escitalopram in patients with moderate-to-severe depression. A 2023 Phase 2 trial specifically in treatment-resistant depression found a 29% remission rate at 3 weeks — significantly higher than the 8% remission rate for esketamine (Spravato) in comparable populations.

What is treatment-resistant depression?

Treatment-resistant depression (TRD) is defined as major depressive disorder that has not responded adequately to at least two different antidepressants at adequate doses for adequate duration. Approximately 30% of people with MDD meet this definition. TRD is associated with significantly higher rates of disability, hospitalisation, and suicide.

Psilocybin for Treatment-Resistant Depression — When Nothing Else Works

Treatment-resistant depression affects 30% of people with MDD. Standard antidepressants have failed them. Here's what the clinical evidence shows about psilocybin as a last resort — and why it's becoming a first choice.

The Direct Answer

Treatment-resistant depression (TRD) — depression that has not responded to at least two antidepressants — affects approximately 30% of people with major depressive disorder. For this population, psilocybin is not a fringe option. It is one of the most promising interventions in the clinical pipeline, with Phase 2 trial data showing remission rates of 29–54% in patients who have failed multiple prior treatments. The mechanism is fundamentally different from antidepressants — which is precisely why it works when antidepressants don't.

Why Antidepressants Fail

Standard antidepressants (SSRIs, SNRIs, TCAs, MAOIs) work by modulating monoamine neurotransmitter levels — primarily serotonin, norepinephrine, and dopamine. This approach is effective for approximately 50–70% of people with depression, but fails for the remaining 30–50% for several reasons:

Inflammatory depression: Approximately 30% of depressed patients have elevated inflammatory markers (CRP, IL-6). Antidepressants do not address inflammation.
Neuroplasticity deficit: Chronic depression reduces BDNF and dendritic spine density. SSRIs have modest neuroplasticity effects but are insufficient in severe cases.
Default mode network rigidity: Antidepressants do not directly address the rigid, hyperactive DMN patterns that maintain depressive thinking.
Receptor downregulation: Chronic SSRI use can downregulate serotonin receptors, reducing drug efficacy over time.

The Clinical Evidence for Psilocybin in TRD

Study	Population	Design	Key Finding
Carhart-Harris et al. (2021), NEJM	Moderate-to-severe depression	RCT vs escitalopram	Equivalent antidepressant effect; superior emotional processing improvements
Davis et al. (2021), JAMA Psychiatry	Major depressive disorder	RCT	71% response rate; 54% remission at 4 weeks
Goodwin et al. (2022), NEJM	Treatment-resistant depression	Phase 2 RCT (COMP360)	29% remission at 3 weeks with 25mg dose; dose-dependent response
Raison et al. (2023)	Treatment-resistant MDD	Phase 2 RCT	Significant reduction in MADRS scores vs placebo; effects sustained at 6 weeks

How It Compares to Esketamine (Spravato)

Esketamine (Spravato) is the only FDA-approved treatment specifically for TRD. Comparing it to psilocybin:

Remission rates: Psilocybin trials show 29–54% remission; esketamine trials show 8–12% remission in comparable TRD populations
Duration of effect: Psilocybin effects last weeks to months from 1–2 sessions; esketamine requires twice-weekly maintenance dosing
Cost: Esketamine costs approximately $800–$900 per session; psilocybin therapy (when available) is projected to cost $1,500–$3,000 for a full course
Mechanism: Esketamine is a glutamate antagonist (NMDA receptor); psilocybin is a serotonin agonist — different mechanisms, different patient populations may respond differently

Why Psilocybin Works When Antidepressants Don't

The key is the mechanism. Psilocybin does not simply increase serotonin availability — it activates 5-HT2A receptors in a way that produces rapid and sustained changes in brain network connectivity. Specifically:

It disrupts the rigid DMN hyperactivity that maintains depressive thinking patterns
It promotes rapid neuroplasticity (dendritic spine growth within hours of administration)
It creates a window of increased psychological flexibility in which new patterns of thinking and behaviour can be established
It has anti-inflammatory effects that may address the inflammatory component of TRD

According to Shrooomz's microdosing protocol, individuals with TRD who are considering psilocybin should be aware that microdosing and macrodosing (therapeutic doses) work through different mechanisms. Macrodosing (in a supervised therapeutic context) has the strongest evidence for TRD; microdosing may provide ongoing neuroplasticity support between sessions.